


EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2910	((544/319) or (514/269)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/08/05 23:45
L2	3338	((544/122,295) or (514/235.8,252.14, 252.18)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/08/05 23:45
L3	1082929	"2007".py.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/08/05 23:45
L4	144	1 and 3	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/08/05 23:45
L5	3458	2 or 4	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/08/05 23:46



chain nodes :

8 9 10 35 36 37 42 43

ring nodes :

1 2 3 4 5 6 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34

ring/chain nodes :

15 16

chain bonds :

2-16 3-15 4-8 5-42 6-43 21-35 27-37 33-36

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 17-18 17-22 18-19 19-20 20-21 21-22 23-24 23-28 24-25 25-26 26-27 27-28 29-30
29-34 30-31 31-32 32-33 33-34

exact/norm bonds :

1-2 1-6 2-3 2-16 3-4 3-15 4-5 5-6 5-42 6-43 21-35 27-37 33-36

exact bonds :

4-8

normalized bonds :

17-18 17-22 18-19 19-20 20-21 21-22 23-24 23-28 24-25 25-26 26-27 27-28 29-30 29-34 30-31 31-32 32-33
33-34

isolated ring systems :

containing 1 : 17 : 23 : 29 :

G1:O,S,N

G2:[*1],[*2],[*3],[*4],[*5]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS9:Atom 10:Atom 15:CLASS16:CLASS17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom
33:Atom 34:Atom 35:CLASS36:CLASS37:CLASS42:CLASS43:CLASS

Generic attributes :

9:
Saturation : Unsaturated
10:
Saturation : Unsaturated
Number of Carbon Atoms : 7 or more
Type of Ring System : Polycyclic

Element Count :

Node 10: Limited
C,C8-18

10/827, 368 (RCE)

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END) :end

=> screen 1840

L1 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L2 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10827368 (RCE A).str



chain nodes :

8 9 10 35 36 37 42 43

ring nodes :

1 2 3 4 5 6 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
33 34

ring/chain nodes :

15 16

chain bonds :

2-16 3-15 4-8 5-42 6-43 21-35 27-37 33-36

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 17-18 17-22 18-19 19-20 20-21 21-22 23-24
23-28 24-25 25-26 26-27 27-28 29-30 29-34 30-31 31-32 32-33 33-34

exact/norm bonds :

1-2 1-6 2-3 2-16 3-4 3-15 4-5 5-6 5-42 6-43 21-35 27-37 33-36

exact bonds :

4-8

normalized bonds :

10/827,368 (RCE)

17-18 17-22 18-19 19-20 20-21 21-22 23-24 23-28 24-25 25-26 26-27 27-28
29-30 29-34 30-31 31-32 32-33 33-34
isolated ring systems :
containing 1 : 17 : 23 : 29 :

G1:O,S,N

G2:[*1], [*2], [*3], [*4], [*5]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:Atom 10:Atom 15:CLASS
16:CLASS 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom
25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom
34:Atom 35:CLASS 36:CLASS 37:CLASS 42:CLASS 43:CLASS

Generic attributes :

9:

Saturation : Unsaturated

10:

Saturation : Unsaturated

Number of Carbon Atoms : 7 or more

Type of Ring System : Polycyclic

Element Count :

Node 10: Limited

C,C8-18

L3 STRUCTURE UPLOADED

=> que L3 AND L1 NOT L2

L4 QUE L3 AND L1 NOT L2

=> d 14

L4 HAS NO ANSWERS

L1 SCR 1840

L2 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L3 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

L4 QUE L3 AND L1 NOT L2

=> s 14 sss sam

SAMPLE SEARCH INITIATED 19:44:39 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 30137 TO ITERATE

6.6% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

1 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 592359 TO 613121

10/827, 368 (RCE)

PROJECTED ANSWERS: 69 TO 533

L5 1 SEA SSS SAM L3 AND L1 NOT L2

=> => s 14 sss ful
FULL SEARCH INITIATED 19:45:10 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 599615 TO ITERATE

100.0% PROCESSED 599615 ITERATIONS 133 ANSWERS
SEARCH TIME: 00.00.09

L6 133 SEA SSS FUL L3 AND L1 NOT L2

=> => s 16
L7 10 L6

=> d 17 1-10 bib,ab,hitstr

L7 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2007:591360 CAPLUS
 DN 147:31135
 TI Pyrimidinone derivatives as calcilytic compounds and their preparation, pharmaceutical compositions and use as calcium receptor inhibitors for treatment of bone and mineral diseases
 IN Ku, Thomas Wen Fu; Lin, Hong; Luengo, Juan I.; Marquis, Robert W., Jr.; Ramanjulu, Joshi M.; Trout, Robert; Yamashita, Dennis S.
 PA Smithkline Beecham Corporation, USA
 SO PCT Int. Appl., 251pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007062370	A2	20070531	WO 2006-US61150	20061121
	W: AE, AG, AL, AM, AT, AU, AZ,	BA, BB, BG, BR, BW, BY, BZ, CA, CH,			
	CN, CO, CR, CU, CZ, DE, DK,	DM, DZ, EC, EE, EG, ES, FI, GB, GD,			
	GE, GH, GM, GT, HN, HR, HU,	ID, IL, IN, IS, JP, KE, KG, KM, KN,			
	KP, KR, KZ, LA, LC, LK, LR,	LS, LT, LU, LV, LY, MA, MD, MG, MK,			
	MN, MW, MX, MY, MZ, NA, NG,	NI, NO, NZ, OM, PG, PH, PL, PT, RO,			
	RS, RU, SC, SD, SE, SG, SK,	SL, SM, SV, SY, TJ, TM, TN, TR, TT,			
	TZ, UA, UG, US, UZ, VC, VN,	ZA, ZM, ZW			
	RW: AT, BE, BG, CH, CY, CZ, DE,	DK, EE, ES, FI, FR, GB, GR, HU, IE,			
	IS, IT, LT, LU, LV, MC, NL,	PL, PT, RO, SE, SI, SK, TR, BF, BJ,			
	CF, CG, CI, CM, GA, GN, GQ,	GW, ML, MR, NE, SN, TD, TG, BW, GH,			
	GM, KE, LS, MW, MZ, NA, SD,	SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,			
	KG, KZ, MD, RU, TJ, TM				

PRAI US 2005-738731P P 20051122
 US 2005-739067P P 20051122

OS MARPAT 147:31135

AB Novel calcilytic compds. of formula I, pharmaceutical compns., methods of synthesis and methods of using them are provided. Compds. of formula I wherein C is O and S; R1 and R2 are independently H, halo, CN; C1-10 alkyl, C2-6 alkenyl, cycloalkyl, (hetero)aryl, etc.; R3 is (un)substituted (hetero)aryl; R4 is (un)substituted (hetero)aryl, (un)substituted heterocyclyl, (un)substituted cycloalkyl-C1-4 alkyl, etc.; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by alkylation of Et 3-oxobutanoate with 3-bromo-2-methyl-1-propene; the resulting Et 2-acetyl-4-methyl-4-pentenoate underwent amidation with phenethylamine to give 2-acetyl-4-methyl-N-(phenethyl)-4-pentenamide, which underwent hydrogenation to give 2-acetyl-4-methyl-N-(phenethyl)-4-pentanamide, which underwent cyclization with 2-fluoro-3-methoxybenzamide to give 2-[2-fluoro-3-methoxyphenyl]-6-methoxy-5-(2-methylpropyl)-3-(2-phenylethyl)-4(3H)-pyrimidinone, which underwent demethylation to give compound II. All the invention compds. were evaluated for their calcium receptor inhibitory activity.


IT 938177-68-5P 938179-84-1P 938179-85-2P
 938179-86-3P 938179-97-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidinone derivs. as calcium receptor inhibitors useful in the treatment of bone and mineral diseases)


RN 938177-68-5 CAPLUS

CN 4(3H)-Pyrimidinone, 3-(2,3-dihydro-1H-inden-2-yl)-2-(2-hydroxyphenyl)-6-methyl-5-(1-methylethyl)- (CA INDEX NAME)




RN 938179-84-1 CAPLUS

CN 4 (3H)-Pyrimidinone, 3-(2,3-dihydro-1H-inden-2-yl)-2-(2-hydroxyphenyl)-6-methyl-5-(5-methyl-2-thienyl)- (CA INDEX NAME)




RN 938179-85-2 CAPLUS

CN Benzonitrile, 3-[1-(2,3-dihydro-1H-inden-2-yl)-1,6-dihydro-2-(2-hydroxyphenyl)-4-methyl-6-oxo-5-pyrimidinyl]- (CA INDEX NAME)




RN 938179-86-3 CAPLUS

CN 4 (3H)-Pyrimidinone, 3-(2,3-dihydro-1H-inden-2-yl)-5-(4,5-dimethyl-2-thiazolyl)-2-(2-hydroxyphenyl)-6-methyl- (CA INDEX NAME)



RN 938179-97-6 CAPLUS

CN 4(3H)-Pyrimidinone, 5-benzo[b]thien-2-yl-3-(2,3-dihydro-1H-inden-2-yl)-2-(2-hydroxyphenyl)-6-methyl- (CA INDEX NAME)




IT 938181-66-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrimidinone derivs. as calcium receptor inhibitors useful in the treatment of bone and mineral diseases)

RN 938181-66-9 CAPLUS

CN 4(3H)-Pyrimidinone, 5-bromo-3-(2,3-dihydro-1H-inden-2-yl)-6-methyl-2-[2-(phenylmethoxy)phenyl]- (CA INDEX NAME)



L7 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2007:329344 CAPLUS
 DN 146:337904
 TI Preparation of pyrimidine carboxamides as inhibitors of cytokines and COX-2
 IN Tadiparthi, Ravikumar; Aggarwal, Pawan; Parameswaran, Venkatesan; Thirunavukkarasu, Sappanmuthu; Bärik, Rajib; Rajagopal, Sriram; Reddy, Gaddam Om
 PA Orchid Research Laboratories Limited, India
 SO PCT Int. Appl., 75pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007031829	A2	20070322	WO 2006-IB2461	20060907
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 2007072876	A1	20070329	US 2006-516549 X	20060907
PRAI	IN 2005-CH1302	A	20050915		


OS MARPAT 146:337904

AB Title compds. represented by the formula I [wherein R = H, halo, amino, etc.; R1, R3 = independently H, SR6 or SOpR7; R2, R4 = independently H, hydroxy, halo, etc.; R5 = H, hydroxy, azido, etc.; and their derivs., analogs, tautomers, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compns. thereof] were prepared as Cyclooxygenase-2 (COX-2) inhibitors. For example, II was provided in a multi-step synthesis starting from 5-cyano-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihdropyrimidine. I were tested in vitro evaluation of COX-2 inhibition activity in human whole blood assay, COX-1 and COX-2 enzyme based assay, in vitro measurement of tumor necrosis factor alpha (TNF- α), and etc. Thus, I and their pharmaceutical compns. are useful for the prophylaxis or treatment of a pain disorder, inflammation, and immunol. diseases in a mammal, which are mediated by TNF- α , IL (1 β , 1,6,8,12) and COX-2 activity.

IT. 613663-83-5, 5-Cyano-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihdropyrimidine 812691-93-3,
 5-Cyano-1-(3,4-dimethylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihdropyrimidine 812692-22-1, 5-Cyano-1-(3,4-dimethylphenyl)-4-(methylthio)-6-oxo-2-(pyridin-3-yl)-1,6-dihdropyrimidine 812692-23-2, 1-(4-Methoxyphenyl)-4-(methylthio)-6-oxo-2-(pyridin-3-yl)-1,6-dihdropyrimidine-5-carbonitrile
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of pyrimidine carboxamides as inhibitors of cytokines and COX-2)


RN 613663-83-5 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)

*Common Inv**w/ ODP*




RN 812691-93-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1-(3,4-dimethylphenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 812692-22-1 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1-(3,4-dimethylphenyl)-1,6-dihydro-4-(methylthio)-6-oxo-2-(3-pyridinyl)- (CA INDEX NAME)



RN 812692-23-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methoxyphenyl)-4-(methylthio)-6-oxo-2-(3-pyridinyl)- (CA INDEX NAME)

10/827, 368 (RCE)



L7 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2007:14078 CAPLUS

DN 146:121982

TI Preparation of pyrazolopyrimidinone derivatives as inhibitors of production of cytokines for treatment of inflammation, cancer, etc.

IN Tadiparthi, Ravikumar; Pushpan, Simi; Rajagopal, Sriram; Barik, Rajib

PA Orchid Research Laboratories Limited; India

SO PCT Int. Appl., 46pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007000655	A2	20070104	WO 2006-IB1791	20060628
	WO 2007000655	A3	20070322		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

not
print

PRAI IN 2005-CH813 A 20050628

OS MARPAT 146:121982

AB The title compds. I [Ar₁, Ar₂ = (un)substituted aryl, heteroaryl, heterocyclyl; R₁ = H, hydroxyl, halo, etc.; R₂ = H, hydroxy, nitro, etc.] are prepared Thus, 3-amino-5-(4-methylphenyl)-6-[4-(methylthio)phenyl]-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one was prepared by from hydrazine hydrate and 5-cyano-1-(4-methylphenyl)-4-methylthio-2-(4-methylthiophenyl)-1,6-dihydropyrimidin-6-one. In an in vitro assay using human peripheral blood mononuclear cells and lipopolysaccharide, compds. of this invention at 10 μM gave 29.8-87.8% inhibition of TNF-α production


IT 613663-83-5 812691-93-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrazolopyrimidinone derivs. as inhibitors of production of cytokines for treatment of inflammation and cancer)

RN 613663-83-5 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



10/827, 368 (RCE)

RN 812691-93-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1-(3,4-dimethylphenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



L7 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:1283525 CAPLUS
 DN 146:45537
 TI Preparation of pyrimidinedione derivatives for treating inflammatory diseases
 IN Tadiparthi, Ravikumar; Aggarwal, Pawan; Reddy, Gaddam Om; Parameswaran, Venkatesan; Rajagopal, Tram, Sr.; Raghveeranathan, Sankaranarayanan
 PA Orchid Research Laboratories Limited, India
 SO PCT Int. Appl., 42pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006129181	A2	20061207	WO 2006-IB1448	20060602
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		not prior

PRAI IN 2005-CH682 A 20050603

OS MARPAT 146:45537

AB Title compds. represented by the formula I [wherein X = O or S; ring A, B = (hetero)aryl; R = H, OH, amino or (halo)alkyl; R1, R3 = independently H, SR5 or SOpR6; R2, R4 = independently H, halo, OH, NO₂, etc.; R5 = H, alkyl(halide), aryl or alkylester; R6 = amino, OH, halo, etc.; Y = -C(=NH)R8 or -C(=NR9)R8; R8, R9 = independently H, amino, azido, etc.; m, n = 0-4; p = 1 or 2], useful for treating inflammatory diseases mediated by cytokines such as TNF- α , IL-1, IL-6, IL-8 and IL-12, were prepared E.g., reaction of 5-cyano-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine with methylamine gave II, which showed TNF- α inhibition with IC₅₀ value of 2.6 μ M. Pharmaceutical composition comprising the compound I is claimed.

IT 916451-81-5P, N-Methyl-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboximidamide
 916451-82-6P, N-Methyl-1-(3,4-dimethylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboximidamide
 916451-83-7P, N-Methyl-1-(4-isopropylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboximidamide
 916451-84-8P, N-Methyl-1-(3,4,5-trimethoxyphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboximidamide
 916451-85-9P 916451-86-0P 916451-87-1P
 916451-88-2P 916451-90-6P 916451-92-8P
 916451-93-9P 916451-94-0P, 2-(4-Methoxyphenyl)-N-methyl-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboximidamide 916451-95-1P 916451-96-2P
 916451-97-3P 916451-98-4P 916451-99-5P
 916452-00-1P 916452-01-2P 916452-03-4P,
 2-[4-(Aminosulfonyl)phenyl]-N-methyl-4-(methylthio)-6-oxo-1-(4-methylphenyl)-1,6-dihydropyrimidine-5-carboximidamide 916452-04-5P
 , 2-[4-(Aminosulfonyl)phenyl]-N-methyl-4-(methylthio)-6-oxo-1-(3,4-dimethylphenyl)-1,6-dihydropyrimidine-5-carboximidamide

Common Inv

no US application pending


916452-05-6P, 2-[4-(Aminosulfonyl)phenyl]-N-methyl-4-(methylthio)-6-oxo-1-(4-fluorophenyl)-1,6-dihdropyrimidine-5-carboximidamide
 916452-07-8P, 1-[4-(Aminosulfonyl)phenyl]-N-methyl-4-(methylthio)-6-oxo-2-(4-methylphenyl)-1,6-dihdropyrimidine-5-carboximidamide
 916452-08-9P, 1-[4-(Aminosulfonyl)phenyl]-N-methyl-4-(methylthio)-6-oxo-2-(3,4-dimethylphenyl)-1,6-dihdropyrimidine-5-carboximidamide
 916452-09-0P, 1-[4-(Aminosulfonyl)phenyl]-N-methyl-4-(methylthio)-6-oxo-2-(4-isopropylphenyl)-1,6-dihdropyrimidine-5-carboximidamide
 916452-10-3P, 1-[4-(Aminosulfonyl)phenyl]-N-methyl-4-(methylthio)-6-oxo-2-(pyridin-3-yl)-1,6-dihdropyrimidine-5-carboximidamide
 916452-11-4P, 1-[4-(Aminosulfonyl)phenyl]-N-methyl-4-(methylthio)-6-oxo-2-(pyridin-4-yl)-1,6-dihdropyrimidine-5-carboximidamide
 916452-12-5P, 1-[4-(Hydrazinosulfonyl)phenyl]-N-methyl-4-(methylthio)-6-oxo-2-(pyridin-4-yl)-1,6-dihdropyrimidine-5-carboximidamide
 916452-13-6P, 1-[4-(Hydrazinosulfonyl)phenyl]-N-methyl-4-(methylamino)-6-oxo-2-(pyridin-4-yl)-1,6-dihdropyrimidine-5-carboximidamide
 916452-14-7P, 1-(4-Methoxyphenyl)-N-methyl-4-(1-methylhydrazino)-6-oxo-2-(pyridin-4-yl)-1,6-dihdropyrimidine-5-carboximidamide
 916452-15-8P, 2-(4-Methylthiophenyl)-N-methyl-4-(1-methylhydrazino)-1-(4-methylphenyl)-6-oxo-1,6-dihdropyrimidine-5-carboximidamide
 916452-16-9P 916452-17-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidinedione derivs. for treating inflammatory diseases)


RN 916451-81-5 CAPLUS

CN 5-Pyrimidinecarboximidamide, 1,6-dihydro-N-methyl-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)




RN 916451-82-6 CAPLUS

CN 5-Pyrimidinecarboximidamide, 1-(3,4-dimethylphenyl)-1,6-dihydro-N-methyl-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)




RN 916451-83-7 CAPLUS

CN 5-Pyrimidinecarboximidamide, 1,6-dihydro-N-methyl-1-[4-(1-methylethyl)phenyl]-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)




RN 916451-84-8 CAPLUS

CN 5-Pyrimidinecarboximidamide, 1,6-dihydro-N-methyl-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 916451-85-9 CAPLUS

CN 5-Pyrimidinecarboximidamide, 1-(4-ethylphenyl)-1,6-dihydro-N-methyl-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)




RN 916451-86-0 CAPLUS

CN 5-Pyrimidinecarboximidamide, 1,6-dihydro-1-(4-methoxyphenyl)-N-methyl-4-(methylthio)-6-oxo-2-(3-pyridinyl)- (CA INDEX NAME)




RN 916451-87-1 CAPLUS

CN 5-Pyrimidinecarboximidamide, 1-(4-fluorophenyl)-1,6-dihydro-N-methyl-4-(methylthio)-6-oxo-2-(4-pyridinyl)- (CA INDEX NAME)




RN 916451-88-2 CAPLUS

CN 5-Pyrimidinecarboximidamide, 1-(3,4-dimethylphenyl)-1,6-dihydro-N-methyl-4-(methylamino)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)




RN 916451-90-6 CAPLUS

CN 5-Pyrimidinecarboximidamide, 1,6-dihydro-N-methyl-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 916451-92-8 CAPLUS

CN 5-Pyrimidinecarboximidamide, 1-(4-fluorophenyl)-1,6-dihydro-N-methyl-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)




RN 916451-93-9 CAPLUS

CN 5-Pyrimidinecarboximidamide, 2-(4-fluorophenyl)-1,6-dihydro-N-methyl-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)




RN 916451-94-0 CAPLUS

CN 5-Pyrimidinecarboximidamide, 1,6-dihydro-2-(4-methoxyphenyl)-N-methyl-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)




RN 916451-95-1 CAPLUS

CN 5-Pyrimidinecarboximidamide, 1,6-dihydro-1-(4-methoxyphenyl)-N-methyl-4-(methylamino)-6-oxo-2-(3-pyridinyl)- (CA INDEX NAME)




RN 916451-96-2 CAPLUS

CN 5-Pyrimidinecarboximidamide, 1-(4-ethylphenyl)-1,6-dihydro-N-methyl-4-(methylamino)-6-oxo-2-(3-pyridinyl)- (CA INDEX NAME)




RN 916451-97-3 CAPLUS

CN 5-Pyrimidinecarboximidamide, 1-(3,4-dimethylphenyl)-1,6-dihydro-N-methyl-4-(methylamino)-6-oxo-2-(4-pyridinyl)- (CA INDEX NAME)




RN 916451-98-4 CAPLUS

CN 5-Pyrimidinecarboximidamide, 1-(3,4-dimethylphenyl)-1,6-dihydro-N-(2-hydroxyethyl)-4-[(2-hydroxyethyl)amino]-6-oxo-2-(3-pyridinyl)- (CA INDEX NAME)




RN 916451-99-5 CAPLUS

CN 5-Pyrimidinecarboximidamide, 1-(4-chlorophenyl)-1,6-dihydro-N-methyl-4-(methylthio)-6-oxo-2-(4-pyridinyl)- (CA INDEX NAME)




RN 916452-00-1 CAPLUS

CN 5-Pyrimidinecarboximidamide, 2-[4-(dimethylamino)phenyl]-1-(3,4-dimethylphenyl)-1,6-dihydro-N-(2-hydroxyethyl)-4-(methylthio)-6-oxo- (CA INDEX NAME)




RN 916452-01-2 CAPLUS

CN 5-Pyrimidinecarboximidamide, 1,6-dihydro-N-methyl-4-(methylthio)-1,2-bis[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)




RN 916452-03-4 CAPLUS

CN 5-Pyrimidinecarboximidamide, 2-[4-(aminosulfonyl)phenyl]-1,6-dihydro-N-methyl-1-(4-methylphenyl)-4-(methylthio)-6-oxo- (CA INDEX NAME)




RN 916452-04-5 CAPLUS

CN 5-Pyrimidinecarboximidamide, 2-[4-(aminosulfonyl)phenyl]-1-(3,4-dimethylphenyl)-1,6-dihydro-N-methyl-4-(methylthio)-6-oxo- (CA INDEX NAME)




RN 916452-05-6 CAPLUS

CN 5-Pyrimidinecarboximidamide, 2-[4-(aminosulfonyl)phenyl]-1-(4-fluorophenyl)-1,6-dihydro-N-methyl-4-(methylthio)-6-oxo- (CA INDEX NAME)




RN 916452-07-8 CAPLUS

CN 5-Pyrimidinecarboximidamide, 1-[4-(aminosulfonyl)phenyl]-1,6-dihydro-N-methyl-2-(4-methylphenyl)-4-(methylthio)-6-oxo- (CA INDEX NAME)




RN 916452-08-9 CAPLUS

CN 5-Pyrimidinecarboximidamide, 1-[4-(aminosulfonyl)phenyl]-2-(3,4-dimethylphenyl)-1,6-dihydro-N-methyl-4-(methylthio)-6-oxo- (CA INDEX NAME)




RN 916452-09-0 CAPLUS

CN 5-Pyrimidinecarboximidamide, 1-[4-(aminosulfonyl)phenyl]-1,6-dihydro-N-methyl-2-[4-(1-methylethyl)phenyl]-4-(methylthio)-6-oxo- (CA INDEX NAME)




RN 916452-10-3 CAPLUS

CN 5-Pyrimidinecarboximidamide, 1-[4-(aminosulfonyl)phenyl]-1,6-dihydro-N-methyl-4-(methylthio)-6-oxo-2-(3-pyridinyl)- (CA INDEX NAME)




RN 916452-11-4 CAPLUS

CN 5-Pyrimidinecarboximidamide, 1-[4-(aminosulfonyl)phenyl]-1,6-dihydro-N-methyl-4-(methylthio)-6-oxo-2-(4-pyridinyl)- (CA INDEX NAME)




RN 916452-12-5 CAPLUS

CN Benzenesulfonic acid, 4-[5-[imino(methylamino)methyl]-4-(methylthio)-6-oxo-2-(4-pyridinyl)-1(6H)-pyrimidinyl]-, hydrazide (CA INDEX NAME)




RN 916452-13-6 CAPLUS

CN Benzenesulfonic acid, 4-[5-[imino(methylamino)methyl]-4-(methylamino)-6-oxo-2-(4-pyridinyl)-1(6H)-pyrimidinyl]-, hydrazide (CA INDEX NAME)




RN 916452-14-7 CAPLUS

CN 5-Pyrimidinecarboximidamide, 1,6-dihydro-1-(4-methoxyphenyl)-N-methyl-4-(1-methylhydrazinyl)-6-oxo-2-(4-pyridinyl)- (CA INDEX NAME)




RN 916452-15-8 CAPLUS

CN 5-Pyrimidinecarboximidamide, 1,6-dihydro-N-methyl-4-(1-methylhydrazinyl)-1-(4-methylphenyl)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)




RN 916452-16-9 CAPLUS

CN 5-Pyrimidinecarboximidamide, 1-(4-chlorophenyl)-1,6-dihydro-N-methyl-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 916452-17-0 CAPLUS


CN 5-Pyrimidinecarboximidamide, 1,6-dihydro-1-(4-methoxyphenyl)-N-methyl-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



IT 613663-83-5, 5-Cyano-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihdropyrimidine 812691-92-2,
 5-Cyano-1-(4-isopropylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihdropyrimidine 812691-96-6, 5-Cyano-1-(3,4,5-trimethoxyphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihdropyrimidine 812692-22-1, 5-Cyano-1-(3,4-dimethylphenyl)-4-(methylthio)-6-oxo-2-(pyridin-3-yl)-1,6-dihdropyrimidine
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of pyrimidinedione derivs. for treating inflammatory diseases)


RN 613663-83-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)




RN 812691-92-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-[4-(1-methylethyl)phenyl]-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)




RN 812691-96-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 812692-22-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1-(3,4-dimethylphenyl)-1,6-dihydro-4-(methylthio)-6-oxo-2-(3-pyridinyl)- (CA INDEX NAME)




L7 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:411890 CAPLUS
 DN 144:450725
 TI Preparation of pyrazolopyrimidinones and analogs, and their compositions as cannabinoid CB1 receptor inhibitors
 IN Liu, Hong; He, Xiaohui; Choi, Ha-Soon; Yang, Kunyong; Woodmansee, David; Wang, Zhicheng; Ellis, David Archer; Wu, Baogen; He, Yun; Nguyen, Truc Ngoc
 PA Irm LLC, Bermuda
 SO PCT Int. Appl., 259 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006047516	A2	20060504	WO 2005-US38361	20051026
	WO 2006047516	A3	20061012		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005299421	A1	20060504	AU 2005-299421	20051026
	CA 2581225	A1	20060504	CA 2005-2581225	20051026
	EP 1807429	A2	20070718	EP 2005-813001	20051026
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				
	NO 2007002352	A	20070531	NO 2007-2352	20070507
PRAI	US 2004-622508P	P	20041026		
	US 2005-672670P	P	20050418		
	WO 2005-US38361	W	20051026		

OS MARPAT 144:450725
 AB Title compds. I [Y = O, NH and derivs., S; R1 = (un)substituted Ph, heteroaryl, cycloalkyl, benzyl; R2 = (un)substituted Ph, OPh, heterocycloalkyl, heteroaryl; R3 = H, halo, OH, CN, etc.; R4 = (un)substituted hetero/aryl, alkyl, etc.; and their pharmaceutically acceptable salts, hydrates, solvates and isomers; with the exception of certain compds.] were prepared as selective cannabinoid CB1 receptor inhibitors. Thus, II was prepared, in 3 steps, starting from 5-amino-1-phenyl-1H-pyrazole-4-carboxylic acid Et ester and 2,4-dichlorobenzoyl chloride. Preferred compds. I showed a 100 fold selectivity for CB1 over CB2 receptor. Pharmaceutical compns. comprising I are useful for preventing and treating diseases or disorders associated with the activity of CB1 receptor, e.g. metabolic disorders.
 IT 885619-00-1P, 1-(4-Bromophenyl)-2-(2-fluorophenyl)-4-methylsulfanyl-6-oxo-1,6-dihdropyrimidine-5-carbonitrile
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of pyrazolopyrimidinones and analogs as CB1 inhibitors)
 RN 885619-00-1 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 1-(4-bromophenyl)-2-(2-fluorophenyl)-1,6-dihydro-

10/827,368 (RCE)

4-(methylthio)-6-oxo- (9CI) (CA INDEX NAME)



L7 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:1215763 CAPLUS
 DN 143:477975
 TI Preparation of pyrimidinones and quinazolinones as calcilytic compounds
 IN Luengo, Juan I.; Marquis, Robert W., Jr.; Xie, Ren; Yamashita, Dennis S.
 PA Smithkline Beecham Corporation, USA
 SO PCT Int. Appl., 34 pp.
 CODEN: PIXXD2

DT Patent
 LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005108376	A1	20051117	WO 2005-US15224	20050503
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1742924	A1	20070117	EP 2005-744198	20050503
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				

PRAI US 2004-568585P P 20040506
 WO 2005-US15224 W 20050503
 OS CASREACT 143:477975; MARPAT 143:477975
 AB The title compds. I [R1, R2 = H, Halo, CN, etc.; or R1 and R2 may be bonded together to form a carbocyclic, heterocyclic, aryl or heteroaryl ring; R3 = aryl or heteroaryl group which may have 1-5 substituents each selected from H, halo, CN, CF₃, etc.; R4 = aryl which may have 1-3 substituents consisting of H, halo, CN, CF₃, etc.; X = O or S], useful for treating a disease or disorder characterized by an abnormal bone or mineral homeostasis, were prepared E.g., a multi-step synthesis of 2-(2-hydroxyphenyl)-3-(4-isopropylphenyl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one, starting from Et 2-aminocyclohex-1-enecarboxylate and 2-benzyloxybenzoyl chloride, was given. The methods for treating diseases or disorders such as osteosarcoma, periodontal disease, fracture healing, osteoarthritis, joint replacement, rheumatoid arthritis, Paget's disease, humoral hypercalcemia, malignancy and osteoporosis by administering the compound I alone or in combination with anti-resorptive agents are disclosed.


IT 869564-58-9P 869564-60-3P 869564-62-5P
 869564-64-7P 869564-68-1P 869564-70-5P
 869564-72-7P 869564-74-9P 869564-76-1P
 869564-98-7P 869564-99-8P 869565-00-4P
 869565-01-5P 869565-02-6P 869565-03-7P
 869565-04-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrimidinones and quinazolinones as calcilytic compds.)
 RN 869564-58-9 CAPLUS
 CN 4(3H)-Pyrimidinone, 5-ethyl-2-(2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 869564-60-3 CAPLUS

CN 4(3H)-Pyrimidinone, 5-ethyl-2-(3-fluoro-2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 869564-62-5 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]-5-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 869564-64-7 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(3-fluoro-2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]-5-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 869564-68-1 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(2-hydroxyphenyl)-5,6-dimethyl-3-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 869564-70-5 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]-5-propyl- (9CI) (CA INDEX NAME)



RN 869564-72-7 CAPLUS


CN 4(3H)-Pyrimidinone, 5-butyl-2-(2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 869564-74-9 CAPLUS


10/827, 368 (RCE)

CN 4 (3H)-Pyrimidinone, 2-(2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 869564-76-1 CAPLUS

CN 4 (3H)-Pyrimidinone, 5-benzo[b]thien-2-yl-2-(2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 869564-98-7 CAPLUS

CN 4 (3H)-Pyrimidinone, 5-benzo[b]thien-2-yl-2-(3-fluoro-2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 869564-99-8 CAPLUS

CN 4 (3H)-Pyrimidinone, 2-(2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]-5-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 869565-00-4 CAPLUS

CN 4 (3H)-Pyrimidinone, 2-(3-fluoro-2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]-5-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 869565-01-5 CAPLUS

CN 4 (3H)-Pyrimidinone, 2-(2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]-5-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)




RN 869565-02-6 CAPLUS

CN 4 (3H)-Pyrimidinone, 2-(3-fluoro-2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]-5-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)




RN 869565-03-7 CAPLUS

CN 4(3H)-Pyrimidinone, 5-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 869565-04-8 CAPLUS

CN 4(3H)-Pyrimidinone, 5-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(3-fluoro-2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



IT 869564-88-5P 869564-95-4P 869564-96-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of pyrimidinones and quinazolinones as calcilytic compds.)


RN 869564-88-5 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(3-fluoro-2-methoxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]-5-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 869564-95-4 CAPLUS

CN 4(3H)-Pyrimidinone, 5-bromo-2-(2-methoxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 869564-96-5 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(2-methoxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)


RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:1075505 CAPLUS
 DN 143:367312
 TI Preparation of novel condensed pyrimidones as cyclooxygenase inhibitors
 IN Agarwal, Shiv Kumar; Tadiparthi, Ravi Kumar; Aggarwal, Pawan; Shivkumar, Savithri
 PA Orchid Chemicals & Pharmaceuticals Ltd., India
 SO PCT Int. Appl., 38 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN CNT 1

Common Inv.


not prior

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005091711	A2	20051006	WO 2005-IB736	20050322
	WO 2005091711	A3	20060309		
				W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
	IN 2004CH00270	A	20051202	IN 2004-CH270	20040324
PRAI	IN 2004-CH270	A	20040324		
OS	MARPAT 143:367312				
AB	The title compds. I [X = O, S; Ar1, Ar2 = (un)substituted aryl, heteroaryl, heterocyclyl; R1, R2 = H, OH, NO ₂ , etc.], useful for lowering plasma concns. of cytokines, and for decreasing cyclooxygenase activity, were prepared Thus, reacting guanidine.HCl with 5-cyano-1-(4-methylphenyl)-4-methylthio-2-(4-methylthiophenyl)-1,6-dihydropyrimidin-6-one in the presence of anhydrous K ₂ CO ₃ in DMF afforded 23% I [X = O; Ar1 = 4-MeC ₆ H ₄ ; Ar2 = 4-(MeS)C ₆ H ₄ ; R1, R2 = NH ₂] which showed 29% COX-2 inhibition and 53% IL-6 inhibition. The present invention relates also to the pharmaceutically acceptable salts and pharmaceutically acceptable compns. containing compds. I.				
IT	613663-83-5, 5-Cyano-1-(4-methylphenyl)-4-methylthio-2-(4-methylthiophenyl)-1,6-dihydropyrimidin-6-one 812691-92-2, 5-Cyano-1-(4-isopropylphenyl)-4-methylthio-2-(4-methylthiophenyl)-1,6-dihydropyrimidin-6-one 812691-93-3, 5-Cyano-1-(3,4-dimethylphenyl)-4-methylthio-2-(4-methylthiophenyl)-1,6-dihydropyrimidin-6-one				
	RL: RCT (Reactant); RACT (Reactant or reagent) (preparation of novel condensed pyrimidones as cyclooxygenase inhibitors)				
RN	613663-83-5 CAPLUS				
CN	5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)				




RN 812691-92-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-[4-(1-methylethyl)phenyl]-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 812691-93-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1-(3,4-dimethylphenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



L7 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:1127094 CAPLUS
 DN 142:74592
 TI Preparation of novel pyrimidones for treating inflammation and immunol. diseases
 IN Agarwal, Shiv Kumar; Tadiparthi, Ravikumar; Aggarwal, Pawan; Shivakumar, Savithiri; Dey, Debendranath; Nag, Biswajit
 PA Orchid Chemical & Pharmaceuticals Limited, India
 SO U.S. Pat. Appl. Publ., 42 pp., Cont.-in-part of U.S. Ser. No. 409,045.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004259891	A1	20041223	US 2004-827368	20040420
	IN 2002MA00266	A	20050304	IN 2002-MA266	20020410
	US 2003225075	A1	20031204	US 2003-409045	20030409
	US 2006194799	A1	20060831	US 2006-414229	20060501
PRAI	IN 2002-MA266	A	20020410		
	US 2003-409045	A2	20030409		
	US 2003-409153	A3	20030409		

OS MARPAT 142:74592


AB The title compds. [I; X = O, S, NR (R = H, OH, acyl, etc.); A, B = (hetero)aryl; R1, R3 = H, SR7, S0pR8 (R7 = H, alkyl, aryl; R8 = halo, alkyl, NH2, acylamino, arylamino, aryl; p = 1-2); R2, R4 = H, halo, OH, etc.; R5, R6 = H, halo, OH, NO2, etc.; n, m = 0-4], useful for treating inflammation and immunol. diseases mediated by cytokines such as TNF- α , IL-1, IL-6, IL-1 β , IL-8 and cyclooxygenase such as COX-2 and COX-3, were prepared Thus, reacting Et 2-cyano-3,3-dimethylthioacrylate with N-(4-methylthiophenyl)-4-fluorobenzamidine (preparation given) afforded II which showed 53.38% COX-2 inhibition. The pharmaceutical compns. comprising the compound I are disclosed.

IT 613663-79-9P 613663-83-5P 812691-93-3P
 812692-27-6P 812692-31-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of novel pyrimidones for treating inflammation and immunol. diseases)

RN 613663-79-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(4-fluorophenyl)-1,6-dihydro-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 613663-83-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-2-


Appl PG Pub

[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)




RN 812691-93-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1-(3,4-dimethylphenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)




RN 812692-27-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,6-dihydro-1-(4-methylphenyl)-4-(methylsulfonyl)-2-[4-(methylsulfonyl)phenyl]-6-oxo- (9CI) (CA INDEX NAME)



RN 812692-31-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(4-fluorophenyl)-1,6-dihydro-4-(methylsulfonyl)-1-[4-(methylsulfonyl)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




IT 613663-78-8P 613663-81-3P 613663-82-4P
 613663-84-6P 613663-85-7P 613663-95-9P
 812691-92-2P 812691-94-4P 812691-95-5P
 812691-96-6P 812691-97-7P 812691-98-8P
 812691-99-9P 812692-01-6P 812692-02-7P
 812692-03-8P 812692-04-9P 812692-05-0P
 812692-07-2P 812692-08-3P 812692-09-4P
 812692-10-7P 812692-11-8P 812692-12-9P
 812692-13-0P 812692-14-1P 812692-15-2P
 812692-16-3P 812692-17-4P 812692-18-5P
 812692-19-6P 812692-20-9P 812692-21-0P
 812692-22-1P 812692-23-2P 812692-24-3P
 812692-25-4P 812692-26-5P 812692-28-7P
 812692-29-8P 812692-30-1P 812692-32-3P
 812692-33-4P 812692-34-5P 812692-35-6P
 812692-36-7P 812692-37-8P 812692-38-9P
 812692-39-0P 812692-41-4P 812692-42-5P
 812692-70-9P 812692-71-0P 812692-72-1P
 812692-73-2P 812692-74-3P 812692-75-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel pyrimidones for treating inflammation and immunol. diseases)

RN 613663-78-8 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-(4-chlorophenyl)-1,6-dihydro-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo- (9CI) (CA INDEX NAME)



RN 613663-81-3 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(methylthio)-1-[4-

(methylthio)phenyl]-6-oxo-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 613663-82-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1-(4-fluorophenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 613663-84-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methylphenyl)-2-[4-(methylsulfonyl)phenyl]-4-(methylthio)-6-oxo- (9CI) (CA INDEX NAME)




RN 613663-85-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 613663-95-9 CAPLUS

CN Benzenesulfonamide, 4-[5-cyano-1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-6-oxo-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 812691-92-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-[4-(1-methylethyl)phenyl]-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)




RN 812691-94-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-[4-(1-methylethyl)phenyl]-2-[4-(methylsulfonyl)phenyl]-4-(methylthio)-6-oxo- (9CI) (CA INDEX NAME)




RN 812691-95-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1-(3,4-dimethylphenyl)-1,6-dihydro-2-[4-(methylsulfonyl)phenyl]-4-(methylthio)-6-oxo- (9CI) (CA INDEX NAME)




RN 812691-96-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 812691-97-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1-(4-ethylphenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 812691-98-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1-(4-bromophenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 812691-99-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methoxyphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 812692-01-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1-(4-chlorophenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 812692-02-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1-(2,4-dimethylphenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 812692-03-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-2-(4-methylphenyl)-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 812692-04-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1-(4-ethoxyphenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 812692-05-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1-[4-(1,1-dimethylethyl)phenyl]-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 812692-07-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1-(4-butylphenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 812692-08-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1-(4-fluorophenyl)-1,6-dihydro-4-(methylthio)-6-oxo-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 812692-09-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1-(4-fluorophenyl)-1,6-dihydro-4-(methylthio)-6-oxo-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 812692-10-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 812692-11-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 812692-12-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1-(4-fluorophenyl)-1,6-dihydro-4-(methylthio)-6-oxo-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 812692-13-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 812692-14-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methoxyphenyl)-4-(methylthio)-6-oxo-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 812692-15-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1-(3,4-dimethylphenyl)-1,6-dihydro-4-(methylthio)-6-oxo-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 812692-16-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1-(4-ethylphenyl)-1,6-dihydro-4-(methylthio)-6-oxo-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 812692-17-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-6-oxo-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 812692-18-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1-(4-ethoxyphenyl)-1,6-dihydro-4-(methylthio)-6-oxo-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 812692-19-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-6-oxo-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 812692-20-9 CAPLUS


CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-[4-(1-methylethyl)phenyl]-4-(methylthio)-6-oxo-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 812692-21-0 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1-(4-ethylphenyl)-1,6-dihydro-4-(methylthio)-6-oxo-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 812692-22-1 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1-(3,4-dimethylphenyl)-1,6-dihydro-4-(methylthio)-6-oxo-2-(3-pyridinyl)- (CA INDEX NAME)




RN 812692-23-2 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methoxyphenyl)-4-(methylthio)-6-oxo-2-(3-pyridinyl)- (CA INDEX NAME)




RN 812692-24-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 812692-25-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1-(4-fluorophenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 812692-26-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-(4-fluorophenyl)-1,6-dihydro-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 812692-28-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,6-dihydro-1-(4-methylphenyl)-2-[4-(methylsulfonyl)phenyl]-6-oxo-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 812692-29-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,6-dihydro-4-(methylamino)-1-(4-methylphenyl)-2-[4-(methylsulfonyl)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 812692-30-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,6-dihydro-1-(4-methylphenyl)-2-[4-(methylsulfonyl)phenyl]-4-(4-morpholinyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 812692-32-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(4-fluorophenyl)-1,6-dihydro-4-(methylamino)-1-[4-(methylsulfonyl)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 812692-33-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(4-fluorophenyl)-1,6-dihydro-1-[4-(methylsulfonyl)phenyl]-4-(4-morpholinyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 812692-34-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 1-(3,4-dimethylphenyl)-1,6-dihydro-4-(methylsulfonyl)-2-[4-(methylsulfonyl)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 812692-35-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(4-fluorophenyl)-1,6-dihydro-4-hydroxy-1-[4-(methylsulfonyl)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 812692-36-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1-(3,4-dimethylphenyl)-1,6-dihydro-4-hydroxy-2-[4-(methylsulfonyl)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 812692-37-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(methylamino)-1-(4-methylphenyl)-2-[4-(methylthio)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 812692-38-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1-(3,4-dimethylphenyl)-1,6-dihydro-4-(methylamino)-2-[4-(methylthio)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 812692-39-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(4-fluorophenyl)-1,6-dihydro-4-(methylamino)-1-[4-(methylthio)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 812692-41-4 CAPLUS

CN Benzenesulfonyl chloride, 4-[5-cyano-1-(3,4-dimethylphenyl)-1,6-dihydro-4-(methylthio)-6-oxo-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 812692-42-5 CAPLUS

CN Benzenesulfonyl chloride, 4-[5-cyano-2-(4-ethoxyphenyl)-4-(methylthio)-6-oxo-1(6H)-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 812692-70-9 CAPLUS

CN Acetamide, N-[[4-[5-cyano-1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-6-oxo-2-pyrimidinyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 812692-71-0 CAPLUS

CN Acetamide, N-[[4-[5-cyano-1-(3,4-dimethylphenyl)-1,6-dihydro-4-(methylthio)-6-oxo-2-pyrimidinyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 812692-72-1 CAPLUS

CN Acetamide, N-[4-[5-cyano-1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-6-oxo-2-pyrimidinyl]phenyl]sulfonyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 812692-73-2 CAPLUS

CN Acetamide, N-[4-[5-cyano-1-(3,4-dimethylphenyl)-1,6-dihydro-4-(methylthio)-6-oxo-2-pyrimidinyl]phenyl]sulfonyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 812692-74-3 CAPLUS

CN Benzamide, N-[4-[5-cyano-1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-6-oxo-2-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 812692-75-4 CAPLUS

CN Benzamide, N-[[4-[5-cyano-1-(3,4-dimethylphenyl)-1,6-dihydro-4-(methylthio)-6-oxo-2-pyrimidinyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:818406 CAPLUS
 DN 139:323531
 TI Preparation of novel pyrimidones for treating inflammation and immunol.
 diseases
 IN Agarwal, Shiv Kumar; Tadiparthi, Ravikumar; Aggarwal, Pawan; Shivakumar,
Savithiri; Dey, Debendranath; Nag, Biswajit
 PA Orchid Chemicals & Pharmaceuticals Limited, India
 SO PCT Int. Appl., 47 pp.

*Same
entity*

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003084938	A2	20031016	WO 2003-IB1306	20030410
	WO 2003084938	A3	20040205		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	IN 2002MA00266	A	20050304	IN 2002-MA266	20020410
	US 2003232813	A1	20031218	US 2003-409161	20030409
	US 2004009975	A1	20040115	US 2003-409153	20030409
	US 7101873	B2	20060905		
	CA 2481825	A1	20031016	CA 2003-2481825	20030410
	AU 2003216592	A1	20031020	AU 2003-216592	20030410
EP 1492774	A2	20050105	EP 2003-712500	20030410	
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1656080	A	20050817	CN 2003-812546	20030410	
JP 2005535570	T	20051124	JP 2003-582135	20030410	
IN 2004CH00353	A	20060526	IN 2004-CH353	20040419	
US 2006194799	A1	20060831	US 2006-414229	20060501	
PRAI	IN 2002-MA266	A	20020410	<i>Priority</i>	
	US 2003-409153	A3	20030409		
	WO 2003-IB1306	W	20030410		

OS MARPAT 139:323531

AB Th title compds. [I; X = O, S, NR (R = H, OH, acyl, etc.); A, B = (hetero)aryl; R1, R3 = SR7, SOpR8 (R7 = alkyl, aryl; R8 = alkyl, NH2, aryl; p = 1-2); R2, R4 = H, halo, OH, etc.; R5, R6 = H, halo, OH, NO2, etc.; n, m = 0-2], useful for treating inflammation and immunol. diseases mediated by cytokines such as TNF- α , IL-1, IL-6, IL-1 β , IL-8 and cyclooxygenase such as COX-2 and COX-3, were prepared and formulated. Thus, reacting Et 2-cyano-3,3-dimethylthioacrylate with N-(4-methylthiophenyl)-4-fluorobenzamidine (preparation given) afforded II which showed 53.38% COX-2 inhibition. Pharmaceutical composition comprising the compound I is claimed.


IT 613663-78-8P 613663-79-9P 613663-81-3P
 613663-82-4P 613663-83-5P 613663-84-6P
 613663-85-7P 613663-92-6P 613663-93-7P
 613663-94-8P 613663-95-9P 613663-96-0P
 613663-97-1P 613663-98-2P 613664-00-9P
 613664-01-0P 613664-07-6P 613664-09-8P

*Not
another*

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of novel pyrimidones for treating inflammation and immunol. diseases)


RN 613663-78-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(4-chlorophenyl)-1,6-dihydro-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 613663-79-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(4-fluorophenyl)-1,6-dihydro-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 613663-81-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 613663-82-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1-(4-fluorophenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 613663-83-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)




RN 613663-84-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methylphenyl)-2-[4-(methylsulfonyl)phenyl]-4-(methylthio)-6-oxo- (9CI) (CA INDEX NAME)




RN 613663-85-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 613663-92-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(4-fluorophenyl)-1,6-dihydro-1-[4-(methylsulfonyl)phenyl]-4-(methylthio)-6-oxo- (9CI) (CA INDEX NAME)




RN 613663-93-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methylphenyl)-4-(methylsulfonyl)-2-[4-(methylsulfonyl)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 613663-94-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methylphenyl)-4-(methylsulfonyl)-2-[4-(methylthio)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 613663-95-9 CAPLUS

CN Benzenesulfonamide, 4-[5-cyano-1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-6-oxo-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 613663-96-0 CAPLUS

CN Benzenesulfonamide, 4-[5-cyano-2-(4-fluorophenyl)-4-(methylthio)-6-oxo-1(6H)-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 613663-97-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,6-dihydro-1-(4-methylphenyl)-2-[4-(methylsulfonyl)phenyl]-4-(methylthio)-6-oxo- (9CI) (CA INDEX NAME)




RN 613663-98-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-(4-fluorophenyl)-1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-6-oxo- (9CI) (CA INDEX NAME)




RN 613664-00-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(4-fluorophenyl)-1,6-dihydro-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 613664-01-0 CAPLUS

CN 4(3H)-Pyrimidinone, 5-chloro-2-(4-chlorophenyl)-6-(methylthio)-3-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 613664-07-6 CAPLUS

CN Benzenesulfonamide, 4-[5-cyano-2-(4-methylphenyl)-4-(methylthio)-6-oxo-1(6H)-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 613664-09-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1-(4-fluorophenyl)-1,6-dihydro-2-[4-(methylsulfonyl)phenyl]-4-(methylthio)-6-oxo- (9CI) (CA INDEX NAME)



L7 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1957:39274 CAPLUS
 DN 51:39274
 OREF 51:7380a-i
 TI Synthesis of 2,3,5,6-substituted 4-pyrimidones
 AU Staskun, Benjamin; Stephen, Henry
 CS Univ. Witwatersrand Johannesburg, S. Afr.
 SO Journal of the Chemical Society (1956) 4708-10
 CODEN: JCSOA9; ISSN: 0368-1769
 DT Journal
 LA Unavailable
 OS CASREACT 51:39274
 AB 2,3,5,6-Substituted 4-pyrimidones (I) were readily synthesized by condensation of imidoyl chlorides (II) with Me or Et α -alkyl- β -aminocrotonates (III). The following general procedure was used: II (0.01 mole) and III (0.005, 0.01, or 0.02 mole) were refluxed 3-4 hrs. in 40 cc. dry CHCl₃ (method A) or allowed to remain at room temperature 2-3 days (method B). In some cases II and III were heated in the absence of a solvent (method C), HCl and alc. being evolved. The products were acidified with dilute HCl and steam distilled; this hydrolyzed any unchanged ester to steam volatile or H₂O soluble products, and converted unchanged II to the amide. After cooling, the latter was removed, and the filtrate treated with C and NH₃ deposited crude I which crystallized from dilute MeOH or alc. in colorless needles. The following I were prepared by the above methods (R and R' substituents in II (RCCl:NR'), R'' and X in III (MeC(NH₂):CR''CO₂X), molar ratio II:III, method, reaction temperature, reaction time in hrs., % yield, and m.p. given): Ph, Ph, Me, Me, 1:1, C, 140°, 0.5, -, -, Ph, Ph, Me, Et, 1:1, C, 140°, 0.5, 45, 157°; Ph, Ph, Et, Et, 1:2, A, -, 4, 79, 159°; Ph, o-C₆H₄Me, Me, Me, 1:1, A, -, 3, 53, 114°; Ph, o-C₆H₄Me, Et, Et, 1:2, A, -, 4, 80, 152°; Ph, m-C₆H₄Me, Me, Me, 1:1, C, 100°, 0.5, 31, 129°; Ph, m-C₆H₄Me, Me, Et, 1:1, C, 100°, 0.5, 28, -, Ph, m-C₆H₄Me, Et, Me, 1:1, C, 100°, 0.5, 77, 136°; Ph, m-C₆H₄Me, Et, Et, 1:2, A, -, 3, -, -, Ph, p-C₆H₄Me, Me, Me, 1:2, A, -, 3, 77, 146°; Ph, p-C₆H₄Me, Et, Et, 1:2, B, -, 3, 75, 152°; Ph, 2,4,1-Me₂C₆H₃, Me, Me, 2:1, A, -, 3, 83, 152°; Ph, 2,4,1-Me₂C₆H₃, Me, Et, 2:1, A, -, 3, -, -, Ph, 2,4,1-Me₂C₆H₃, Et, Et, 2:1, A, -, 3, 83, 146°; Ph, p-MeOC₆H₄, Et, Et, 1:2, B, -, 3, 81, 161°; Ph, p-MeOC₆H₄, Pr, Me, 1:2, C, 155°, 0.5, 55, 163°; Ph, m-O₂NC₆H₄, Me, Me, 1:2, C, 140°, 0.5, 62, 159°; Ph, m-O₂NC₆H₄, Me, Et, 1:2, C, 140°, 0.5, 34, -, Ph, m-O₂NC₆H₄, Et, Me, 1:2, C, 140°, 0.5, 24, 160°; Ph, m-O₂NC₆H₄, Et, Et, 1:2, C, 140°, 0.5, 38, -; Ph, 1-C₁₀H₇, Me, Et, 1:2, A, -, 3, 64, 174°; Ph, 2-C₁₀H₇, Me, Et, 1:2, A, -, 3, 50, 189°; Ph, 2-C₁₀H₇, Et, Et, 1:2, A, -, 3, 40, 184°; Ph, o-C₆H₄Cl, Me, Et, 2:1, A, -, 3, 13, 151°; Ph, o-C₆H₄Cl, Et, Et, 2:1, C, 170°, 0.5, 32, 192°; Ph, m-C₆H₄Cl, Me, Me, 1:1, C, 150°, 0.5, 35, 152°; Ph, p-C₆H₄Cl, Et, Et, 1:2, C, 185°, 0.5, 59, 148°; Ph, p-C₆H₄Cl, Pr, Me, 1:2, C, 185°, 0.5, 37, 154°; Ph, Et, Et, Et, 1:2, B, -, 3, 73, 82°; Ph, Et, Me, Et, 1:2, B, -, 3, 51, 118°; o-C₆H₄Me, Ph, Me, Me, 2:1, A, -, 3, 80, 112°; o-C₆H₄Me, Ph, Et, Et, 2:1, A, -, 3, 74, 137°; p-C₆H₄Cl, Ph, Et, Et, 1:2, C, 155°, 0.5, 67, 146°; p-C₆H₄Cl, Ph, Pr, Me, 1:2, C, 155°, 0.5, 21, 151°; 3,4,5-(MeO)3C₆H₂, Ph, Me, Me, 1:2, A, -, 3, 20, 181°; 3,4,5-(MeO)3C₆H₂, Ph, Et, Et, 1:2, A, -, 3, 37, 129°. The synthesis of I was modified by preparing II by rearrangement of ketoximes (IV) with PCl₅. The following procedures were used. A solution of IV (0.01 mole) in 50 cc. CHCl₃ was treated at 0° with 0.01 mole PCl₅, the whole shaken 1-2 min., and the solution treated by one of the following procedures. The solution refluxed 15 min. to complete the rearrangement of


IV, the III (0.02-0.03 mole) added in 10 cc. CHCl₃, and reflux continued 2-3 hrs. (method D). Alternatively, the solution after remaining 2 hrs. at room temperature was cooled to 10°, the III (0.02-0.03 mole) in 10 cc. CHCl₃ added, and the mixture left 1-2 days at room temperature (method E). The following method (F) gave good yields of I. The solution of rearranged IV, after 2 hrs. at room temperature was distilled at 40-5°/30 min., then stored 1-2 days with 0.02-0.03 mole III, and the products treated as previously described. I were crystallized as colorless needles from MeOH or alc. The following results were obtained (IV, R' in III, method, % yield, and m.p. of I given): PhMeC:NOH, Et, E, 65, 126°; (p-MeC₆H₄)MeC:NOH, Et, E, 65, 82°; (p-MeC₆H₄)MeC:NOH, Me, D, 65, 146°; 2-C₁₀H₇CMe:NOH, Et, F, 65, 130°; PhPrC:NOH, Et, E, 72, 106°; PhPrC:NOH, Me, E, 35, 73°; (p-MeC₆H₄)₂C:NOH, Me, F, 73, 128°; (p-MeC₆H₄)₂C:NOH, Et, F, 60, 140°; Ph₂C:NOH, Et, D, 55, 157°. Improved yields of I were obtained by using excess II or III.

IT 102316-51-8P, 4(3H)-Pyrimidinone, 5,6-dimethyl-2,3-di-p-tolyl-
102660-46-8P, 4(3H)-Pyrimidinone, 5-ethyl-6-methyl-2,3-di-p-tolyl-

RL: PREP (Preparation)
(preparation of)


RN 102316-51-8 CAPLUS

CN 4(3H)-Pyrimidinone, 5,6-dimethyl-2,3-di-p-tolyl- (6CI) (CA INDEX NAME)



RN 102660-46-8 CAPLUS

CN 4(3H)-Pyrimidinone, 5-ethyl-6-methyl-2,3-di-p-tolyl- (6CI) (CA INDEX NAME)



10/827, 368 (RCE)

=> => d his

(FILE 'HOME' ENTERED AT 19:43:58 ON 05 AUG 2007)

FILE 'REGISTRY' ENTERED AT 19:44:08 ON 05 AUG 2007

L1 SCREEN 1840
L2 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L3 STRUCTURE UPLOADED
L4 QUE L3 AND L1 NOT L2
L5 1 S L4 SSS SAM
L6 133 S L4 SSS FUL

FILE 'CAPLUS' ENTERED AT 19:45:26 ON 05 AUG 2007


L7 10 S L6

FILE 'CAOLD' ENTERED AT 19:46:09 ON 05 AUG 2007


=> s 16
L8 1 L6

=> d 18 bib,hitstr

L8 ANSWER 1 OF 1 CAOLD COPYRIGHT 2007 ACS on STN
AN CA51:7380a CAOLD
TI synthesis of 2,3,5,6-substituted 4-pyrimidones
AU Staskun, Benjamin; Stephen, H.
IT 102316-51-8 102660-46-8
RN 102316-51-8 CAOLD
CN 4(3H)-Pyrimidinone, 5,6-dimethyl-2,3-di-p-tolyl- (6CI) (CA INDEX NAME)



RN 102660-46-8 CAOLD
CN 4(3H)-Pyrimidinone, 5-ethyl-6-methyl-2,3-di-p-tolyl- (6CI) (CA INDEX NAME)



10/827,368 (RCE)

=> log y COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.47	229.40
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-7.80

STN INTERNATIONAL LOGOFF AT 19:46:33 ON 05 AUG 2007